Alnylam Pharmaceuticals, Inc. (ALNY): John Maraganore , CEO of Alnylam Pharmaceuticals, Inc. sold 30,151 shares on Jul 19, 2016. The Insider selling transaction was reported by the company on Jul 21, 2016 to the Securities and Exchange Commission. The shares were sold at $64.83 per share for a total value of $1,950,590.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 21, 2016, John Maraganore (Chief Executive Officer) sold 30,151 shares at $67.87 per share price.On Mar 10, 2016, Michael W Bonney (director) purchased 2,000 shares at $58.36 per share price.Also, On Feb 3, 2016, Sanofi (10% owner) purchased 205,030 shares at $69.75 per share price.On Dec 4, 2015, Philip A Sharp (director) sold 30,000 shares at $109.00 per share price.
Alnylam Pharmaceuticals: On Wednesday, Jul 20, 2016 heightened volatility was witnessed in Alnylam Pharmaceuticals which led to swings in the share price. The shares opened for trading at $64.28 and hit $66.23 on the upside , eventually ending the session at $65.74, with a gain of 2.67% or 1.71 points. The heightened volatility saw the trading volume jump to 6,66,890 shares. The 52-week high of the share price is $136.7699 and the company has a market cap of $5,625 M . The 52-week low of the share price is at $49.96.
Company has been under the radar of several Street Analysts.Alnylam Pharmaceuticals is Reiterated by Chardan Capital Markets to Buy and the brokerage firm has raised the Price Target to $ 115 from a previous price target of $93 .The Rating was issued on May 26, 2016.
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Companys pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease with a pipeline of RNAi therapeutics toward genetically validated liver-expressed disease in cardiovascular and metabolic diseases and hepatic infectious disease with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02) Revusiran (ALN-TTRsc) ALN-AT3 ALN-CC5 ALN-AS1 ALN-AAT ALN-GO1 ALN-TMP ALN-PCS ALN-PCSsc ALN-AC3 ALN-ANG ANGPTL3 ALN-HBV ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.